Education, Conference Coverage and Articles
The VERITAC-2 trial is a pivotal, randomized phase III trial evaluating vepdegestrant, a novel oral PROTAC estrogen receptor degrader, in patients with ER-positive, HER2-negative advanced breast cancer. In this interview, Dr Erika Hamilton (Director, Breast Cancer Research, Sarah Cannon ...
ASCO 2025 showcased transformative breast cancer data. The SERENA-6 trial introduced a novel ctDNA-driven approach for ESR1 mutations, improving PFS with camizestrant. DESTINY-Breast09 supported trastuzumab deruxtecan in first-line HER2-positive disease, while ASCENT-04 showed promise for sacituzumab govitecan plus immunotherapy in triple-negative breast cancer—heralding major shifts in clinical practice.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more supportive healthcare culture.
At #ASCO25, key neuro-oncology presentations explored focused ultrasound to enhance drug delivery, the benefits of maximal surgical resection in IDH-mutant gliomas, and final CATNON data supporting adjuvant temozolomide. Other highlights included improved cognitive outcomes with stereotactic radiosurgery for brain metastases and early results from a novel gamma delta T cell therapy.
At #ASCO25, Professor Dickon Hayne presented results from the ANZUP 1301 trial showing that adding mitomycin C to BCG may offer a well-tolerated, effective option for high-risk NMIBC. The combination reduced BCG use by 40% – a significant finding amid global shortages – with encouraging efficacy and safety signals.
Dr. Sara Tolaney discusses ASCENT-04, a phase III trial showing that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival versus chemotherapy plus pembrolizumab in PD-L1–positive metastatic TNBC. With a PFS of 11.2 months and a hazard ratio of 0.65, the combination may represent a new first-line treatment standard.
DESTINY-Breast09 interim results show that trastuzumab deruxtecan plus pertuzumab significantly improves progression-free survival compared to standard THP in first-line treatment for metastatic HER2-positive breast cancer. With a median PFS of 40.7 months versus 26.9 months, the data suggest a potential shift in the treatment paradigm.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is being held 30th May - 3rd June in Chicago, IL, USA. Under the theme 'Driving Knowledge to Action: Building a Better Future,' #ASCO25 is set to welcome 40,000 oncology professionals, researchers and advocates from around the globe.
The European Oncology Nursing Society (EONS) recognized early the unique challenges that new generations of cancer nurses experience on a personal and professional level, as a result of rapid political and economic changes globally. Therefore, in 2017, in response to the needs and motivations of Young Cancer Nurses (YCN), EONS supported the development of a network for “cancer nurses and general nurses who work in cancer settings and / or with people affected by cancer in the WHO Europe region, who are under the age of 35”.
At a time when cancer research is experiencing uncertainty and setbacks in America, the Colorectal Cancer Alliance (Alliance) is strengthening its commitment to its Project Cure CRC initiative because tomorrow can’t wait. Project Cure CRC funds cutting-edge colorectal cancer (CRC) research and aims to improve patient outcomes through its dynamic patient navigation portal, BlueHQ.org.
This May, the World Bladder Cancer Patient Coalition (WBCPC) is launching Bladder Cancer Awareness Month 2025 under the theme “Feeling Unsure? Get Checked”. The campaign highlights the importance of recognising blood in urine as a symptom of bladder cancer and acting quickly to seek medical advice.
Dr Satish Nadig describes Northwestern Medicine’s first use of the RAPID procedure to treat metastatic colorectal cancer with liver transplantation. He outlines the innovative surgical techniques, the promise of the CLEAR program, and the future potential of machine perfusion technology to extend transplant opportunities to more patients.
Dr Soo Park reflects on the profound impact of mentorship, emphasizing patience and the importance of finding one’s voice. She finds fulfillment in combining science and compassion to support her patients and draws ongoing inspiration from their milestones, viewing her work in oncology as both a privilege and a source of purpose.
BUDAPEST – With a history of medical innovation stretching from Ignaz Semmelweis's groundbreaking antiseptic methods to Endre Mester's pioneering work in laser therapy, Budapest has long played a role in advancing medical science. This May, the tradition continues as the paediatric ...
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.